Table 5. Number of participants hospitalised with related diagnoses in SPACE compared with control groups in the 12 months following baseline, adjusting for hospitalisations in the 12 months before baseline, patient age at baseline, and number of prescribed medications at baseline.
| 12 months before baseline, n/N (%) | 12 months after baseline, n/N (%) | OR (95% CI) | P value | |||
|---|---|---|---|---|---|---|
| SPACE | Control | SPACE | Control | |||
| Combined risk factor | 350/11 658 (3.0%) | 359/10 209 (3.5%) | 371/11 658 (3.2%) | 364/10 209 (3.6%) | 0.96 (0.82–1.11) | 0.5a |
| Gastrointestinal | 116/8711 (1.3%) | 116/7465 (1.6%) | 112/8711 (1.2%) | 99/7465 (1.3%) | 1.03 (0.78–1.35) | 0.9 |
| Renal | 76/6268 (1.2%) | 75/5588 (1.3%) | 77/6268 (1.2%) | 86/5588 (1.5%) | 0.84 (0.62–1.15) | 0.3 |
| Heart failure | 90/613 (14.7%) | 76/627 (12.1%) | 56/613 (9.1%) | 66/627 (10.5%) | 0.85 (0.57–1.25) | 0.4 |
aOwing to the small number of hospitalisations in each practice, clustering could not be used in any model except this one. When clustering, sex and ethnicity were included in the model the P value was 0.3.
OR = odds ratio. SPACE = Safer Prescribing and Care for the Elderly.